{
    "Clinical Trial ID": "NCT01735175",
    "Intervention": [
        "INTERVENTION 1: ",
        "  LA-EP2006",
        "  During each chemotherapy cycle eligible patients receive LA-EP2006 s.c. post chemotherapy application.",
        "  LA-EP2006: Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.",
        "INTERVENTION 2: ",
        "  Neulasta\u00ae",
        "  During each chemotherapy cycle eligible patients receive Neulasta\u00ae s.c. post chemotherapy application.",
        "  Neulasta\u00ae: Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  histologically proven breast cancer",
        "  eligible for six cycles of neoadjuvant or adjuvant chemotherapy",
        "Exclusion Criteria:",
        "  concurrent or prior chemotherapy for breast cancer",
        "  concurrent or prior anti-cancer treatment for breast cancer such as endocrine therapy, immunotherapy, monoclonal antibodies, and/or biological therapy",
        "  concurrent prophylactic antibiotics",
        "  previous therapy with any G-CSF (granulocyte-colony stimulating factor) product",
        "  Other protocol-defined inclusion/exclusion criteria may apply."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Mean Duration of Severe Neutropenia (DSN) During Cycle 1 of Chemotherapy",
        "  Mean duration of severe neutropenia, defined as number of consecutive days with ANC <0.5 \u00d7 10^9 cells/L (grade 4 neutropenia).",
        "  Time frame: 21 days (Cycle 1 of chemotherapy treatment)",
        "Results 1: ",
        "  Arm/Group Title: LA-EP2006",
        "  Arm/Group Description: During each chemotherapy cycle eligible patients receive LA-EP2006 s.c. post chemotherapy application.",
        "  LA-EP2006: Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.",
        "  Overall Number of Participants Analyzed: 159",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: days  FAS: 155 participants",
        "  0.75         (0.878)",
        "  PP: 146 participants",
        "  0.75         (0.875)",
        "Results 2: ",
        "  Arm/Group Title: Neulasta  ",
        "  Arm/Group Description: During each chemotherapy cycle eligible patients receive Neulasta   s.c. post chemotherapy application.",
        "  Neulasta  : Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.",
        "  Overall Number of Participants Analyzed: 157",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: days  FAS: 155 participants",
        "  0.83         (0.898)",
        "  PP: 149 participants",
        "  0.79         (0.872)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 16/159 (10.06%)",
        "  Febrile neutropenia  9/159 (5.66%)",
        "  Neutropenia  3/159 (1.89%)",
        "  Anemia  1/159 (0.63%)",
        "  Leukopenia  0/159 (0.00%)",
        "  Pancytopenia  0/159 (0.00%)",
        "  Thrombocytopenia  0/159 (0.00%)",
        "  Cardio-respiratory arrest  2/159 (1.26%)",
        "  Cardiac arrest  1/159 (0.63%)",
        "  Diarrhea  0/159 (0.00%)",
        "  Gastritis  1/159 (0.63%)",
        "  Nausea  1/159 (0.63%)",
        "  Vomiting  0/159 (0.00%)",
        "Adverse Events 2:",
        "  Total: 21/157 (13.38%)",
        "  Febrile neutropenia  12/157 (7.64%)",
        "  Neutropenia  6/157 (3.82%)",
        "  Anemia  2/157 (1.27%)",
        "  Leukopenia  1/157 (0.64%)",
        "  Pancytopenia  1/157 (0.64%)",
        "  Thrombocytopenia  1/157 (0.64%)",
        "  Cardio-respiratory arrest  0/157 (0.00%)",
        "  Cardiac arrest  0/157 (0.00%)",
        "  Diarrhea  1/157 (0.64%)",
        "  Gastritis  0/157 (0.00%)",
        "  Nausea  0/157 (0.00%)",
        "  Vomiting  1/157 (0.64%)"
    ]
}